Literature DB >> 33108860

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Comparison of Pre- and Post-Public-Private Mix Periods.

Yewon Kang1, Eun-Jung Jo2, Jung Seop Eom2,3, Mi-Hyun Kim2,3, Kwangha Lee2,3, Ki Uk Kim2,3, Hye-Kyung Park2,3, Min Ki Lee2,3, Jeongha Mok2,3,4.   

Abstract

BACKGROUND: This study compared the treatment outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) before and after the implementation of public-private mix (PPM). Factors affecting treatment success were also investigated.
METHODS: Data from culture-confirmed pulmonary MDR-TB patients who commenced MDR-TB treatment at Pusan National University Hospital between January 2003 and December 2017 were retrospectively reviewed. Patients were divided into two groups in terms of PPM status: pre-PPM period, patients who commenced MDR-TB treatment between 2003 and 2010; and post-PPM period, patients treated between 2011 and 2017.
RESULTS: A total of 176 patients were included (64 and 112 in the pre- and post-PPM periods, respectively). 36.9% of the patients were resistant to a fluoroquinolone or a second-line injectable drug, or both. The overall treatment success rate was 72.7%. The success rate of post-PPM patients was higher than that of pre-PPM patients (79.5% vs. 60.9%, p=0.008). Also, loss to follow-up was lower in the post-PPM period (5.4% vs. 15.6%, p=0.023). In multivariate regression analysis, age ≥65 years, body mass index ≤18.5 kg/m2, previous TB treatment, bilateral lung involvement, and extensively drug-resistant (XDR)- or pre-XDR-TB were associated with poorer treatment outcomes. However, the use of bedaquiline or delamanid for ≥1 month increased the treatment success.
CONCLUSION: The treatment success rate in MDR-TB patients was higher in the post-PPM period than in the pre-PPM period, particularly because of the low rate of loss to follow-up. To ensure comprehensive patient-centered PPM in South Korea, investment and other support must be adequate.

Entities:  

Keywords:  Multidrug-Resistant Tuberculosis; PPM; Public–Private Mix; South Korea; Treatment Outcome

Year:  2020        PMID: 33108860     DOI: 10.4046/trd.2020.0093

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  4 in total

1.  Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study.

Authors:  Temesgen Sidamo; Workineh Shibeshi; Getnet Yimer; Eleni Aklillu; Ephrem Engidawork
Journal:  Infect Drug Resist       Date:  2021-12-18       Impact factor: 4.177

2.  Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors' Reply.

Authors:  Yewon Kang; Jeongha Mok
Journal:  Tuberc Respir Dis (Seoul)       Date:  2021-09-13

3.  Hidden loss to follow-up among tuberculosis patients managed by public-private mix institutions in South Korea.

Authors:  Hyung Woo Kim; Sohee Park; Helen R Stagg; Ju Sang Kim; Jinsoo Min; Jiyu Sun; Ah Young Shin; Jick Hwan Ha; Jae Seuk Park; Sung-Soon Lee; Marc Lipman; Ibrahim Abubakar
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

4.  Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data.

Authors:  Sun-Hong Kwon; Jin Hyun Nam; Hye-Lin Kim; Hae-Young Park; Jin-Won Kwon
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.